Mukherjee, Sudip
Kim, Boram http://orcid.org/0000-0002-4758-4547
Cheng, Lauren Y. http://orcid.org/0000-0001-7692-5446
Doerfert, Michael David
Li, Jiaming http://orcid.org/0000-0003-2051-9224
Hernandez, Andrea
Liang, Lily http://orcid.org/0000-0003-1907-6008
Jarvis, Maria I.
Rios, Peter D.
Ghani, Sofia
Joshi, Ira
Isa, Douglas
Ray, Trisha
Terlier, Tanguy
Fell, Cody
Song, Ping
Miranda, Roberto N. http://orcid.org/0000-0002-8467-5464
Oberholzer, Jose
Zhang, David Yu http://orcid.org/0000-0002-0213-7663
Veiseh, Omid http://orcid.org/0000-0003-1153-8079
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK120459, R01 DK120459)
Article History
Received: 23 February 2022
Accepted: 27 February 2023
First Online: 27 April 2023
Competing interests
: O.V. is cofounder and significant shareholder of Sigilon Therapeutics, Avenge Bio and Pana Bio. D.Y.Z. owns significant equity in and receives consulting income from NuProbe Global and Torus Biosystems, and owns significant equity in Pana Bio. J.O. is a founding scientist and significant shareholder of Sigilon Therapeutics and CellTrans Inc.